Zurich-based Rivia Raises €13 Million to Revolutionize Clinical Trials with AI-Driven Data Engine

In a significant boost for the biotech industry, Zurich-based startup Rivia has secured a €13 million ($15 million) Series A funding round. This investment is set to propel Rivia's mission to streamline complex clinical trials through its innovative agentic data engine. The round was spearheaded by Earlybird, with notable contributions from Defiant and existing investors Speedinvest, Amino Collective, and Nina Capital.

Transforming Clinical Trials with AI

Founded in 2022 by Erik Scalfaro and Tiago Kieliger, Rivia is at the forefront of a technological revolution in clinical trial management. The startup specializes in AI-driven analytics and clinical trial data infrastructure, offering a cutting-edge solution to the burgeoning complexities of drug development. Scalfaro explains that their strategic focus on building a robust foundational data engine before advancing to AI agents provides a unique advantage in the field.

“BioTechs running global trials on our platform have seen transformative results,” Scalfaro stated. “From preventing costly issues to understanding patient benefits sooner, our approach compounds value with each trial.”

Addressing Industry Challenges

The biotech industry faces mounting challenges, including increased regulatory scrutiny and declining economic returns. With FDA guidelines now encouraging innovation in trial design and execution, Rivia's technology is well-positioned to meet these demands. The company's platform integrates thousands of data files in real-time, applying trial-specific scientific logic to streamline operational workflows.

The data engine serves as a reusable intelligence layer, enhancing decision-making and reducing manual efforts significantly. Rivia’s first AI agent, Spark, converts natural language into high-quality clinical visualizations, while other agents focus on proactive data quality monitoring.

Implications for Startups and Investors

Rivia's success is a promising indicator for startups in the biotech and healthcare sectors. By addressing the inefficiencies and high costs associated with clinical trials, Rivia is paving the way for more sustainable drug development processes. For investors, the company represents a lucrative opportunity in a market desperate for innovation and efficiency.

Christian Nagel, Partner at Earlybird, emphasized the potential impact: “Rivia’s intelligence layer is a game-changer for clinical operations. We’re thrilled to support their journey to reshape global drug development.”

A Vision for the Future

Rivia's achievements over the past two years underscore its potential. The company has supported 40 clinical trials across the US and Europe, achieving a fourfold increase in annual recurring revenue by 2025. With a €3 million Seed round secured in 2024, Rivia is poised for further expansion.

Looking ahead, Rivia aims to reduce clinical trial costs by up to 50%, leveraging AI and data unification to replace labor-intensive processes. This ambitious goal could significantly accelerate the introduction of innovative therapies to the market.

In conclusion, Rivia's €13 million funding round marks a pivotal moment in its journey to transform clinical trials. By harnessing the power of AI, the startup is not only enhancing the efficiency and effectiveness of drug development but also setting a new standard for innovation in the biotech industry.

Source: EU-Startups